Overview

Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Status:
COMPLETED
Trial end date:
2021-11-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
Phase:
PHASE3
Details
Lead Sponsor:
Addpharma Inc.